Glucose intolerance during hormonal therapy for prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 4, 2007, Pages 384-387

  Suzuki, K ^a,b   Nukui, A ^a   Hara, Y ^b   Morita, T ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Utsunomiya Shakaihoken Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIDIABETIC AGENT; GLUCOSE; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER HORMONE THERAPY; CANCER PATIENT; COMORBIDITY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET THERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS; GLUCOSE INTOLERANCE; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; PROSTATIC NEOPLASMS;

EID: 36949040400     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500976     Document Type: Article

References (12)

1. Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol 2005; 12: 662-667.
2. Cancer registration committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61.
3. Suzuki K, Kobayashi M, Tokue A. Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma. Nippon Hinyokika Gakkai Zasshi 2003; 94: 614-620.
4. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in male with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261-4267.
5. Basaria S, Lieb II J, Tang AM, DcWeese T, Carducci M, Eisenberger M et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002; 56: 779-786.
6. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-745.
7. Smith MR, Finkelstein JS, McGovern FJ, Zictman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87 599-603.
8. Inaba M, Otani Y, Nishimura K, Takaha N, Okuyama A, Koga M et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005; 54: 55-59.
9. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-588.
10. Schattner A, Katz-Porat BS, Gindin Y, Geltner D. Cyproterone-induced hyperosmolar hyperglycemia. Drug Intell Clin Pharm 1988; 22: 632-633.
11. Coddington CC, Hassiakos DK, Harrison HC, Brzyski RG, Jones GS. Effect of a gonadotropin-releasing hormone analogue on the glucose metabolism in a diabetic patient. Gynecol Obstet Invest 1990; 30: 246-248.
12. Morimoto S, Fernandez-Mejia C, Romero-Navarro G, Morales-Peza N, Diaz-Sanchez V. Testosterone effect on insulin content, messenger ribonucleic acid levels, promoter activity, and secretion n the rat. Endocrinology 2001; 142: 1442-1447.